Third-generation EGFR tyrosine kinase inhibitor

This page covers all Third-generation EGFR tyrosine kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting EGFR (Epidermal Growth Factor Receptor), EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M, EGFR (epidermal growth factor receptor).

Targets

EGFR (Epidermal Growth Factor Receptor) · EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M · EGFR (epidermal growth factor receptor)

Phase 3 pipeline (4)

• AZD9291 · Soroka University Medical Center · Oncology
  AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to mutant EGFR while sparing wild-type EGFR, overcoming resistance from the T790M mutation.
• Firmonertinib Mesilate Tablets · Allist Pharmaceuticals, Inc. · Oncology
  Firmonertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.
• SHR-A2009 ; Aumolertinib · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
  Aumolertinib is a third-generation EGFR tyrosine kinase inhibitor that selectively targets EGFR mutations, including T790M resistance mutations, to inhibit tumor cell proliferation.
• Furmonertinib Mesilate Tablets · Allist Pharmaceuticals, Inc. · Oncology
  Furmonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.

Phase 2 pipeline (1)

• Alomnertinib Mesilate · Shanghai Hengrui Pharmaceutical Co., Ltd. · Oncology
  Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.